Tenofovir Approved: Broad IndicationOctober 26, 2001 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! On October 26 the FDA approved Viread -- generic name tenofovir disoproxil fumarate, or tenofovir DF. The approval was expected; less expected was the broad indication, which both the company and treatment activists wanted, but which some of the advisory committee had questioned (see "Tenofovir: FDA Hearing on Important New Antiretroviral," AIDS Treatment News #372, October 19, 2001). From the package insert:
The Medscape drug-interaction calculator, recently updated to include tenofovir, is here. (Free registration required.) An FDA Talk Paper is here. And the complete package insert can be found on the Gilead site here. Copyright 2001 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
|
|